RSS Feeds
Acute Hepatotoxicity Caused by Repaglinide
- Daniel N. Nan, MD;
- José L. Hernández, MD, PhD;
- Marta Fernández-Ayala, MD; and
- Miguel Carrascosa, MD
- From University Hospital Marqués de Valdecilla, and Hospital Comarcal de Laredo, 39008 Santander, Spain.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Repaglinide is a short-acting, orally administered drug used to control postprandial hyperglycemia in patients with …
